Five Prime Therapeutics (FPRX) Posts Q4 Loss of 55c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Five Prime Therapeutics (FPRX) Posts Q4 Loss of 55c/Share
March 17, 2015 4:05 PM EDT
SOUTH SAN FRANCISCO, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014.
"2014 was a remarkable year for Five Prime," said Lewis T. "Rusty" Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime. "We began the year with two candidates in the clinic and our pipeline has now grown to three clinical-stage therapeutics covering 11... More
March 17, 2015 4:05 PM EDT
SOUTH SAN FRANCISCO, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014.
"2014 was a remarkable year for Five Prime," said Lewis T. "Rusty" Williams, M.D., Ph.D., Founder and Chief Executive Officer of Five Prime. "We began the year with two candidates in the clinic and our pipeline has now grown to three clinical-stage therapeutics covering 11... More
